CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
albumin-bound paclitaxel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02525653
NCT02525653Phase 2Completed

A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

Memorial Sloan Kettering Cancer Center·interventional·Posted Aug 17, 2015·Updated Jan 12, 2021

In Brief

A Phase 2 clinical trial evaluating albumin-bound paclitaxel and gemcitabine for Lung Cancer and Untreated Stage IV or Recurrent Squamous Cell Lung Cancers. Completed, enrolled 40 participants across 6 sites.

Detailed Summary

The purpose of this study is to test the safety and effectiveness of albumin-bound paclitaxel plus gemcitabine in patients with advanced squamous cell lung cancers. The investigators would like to determine the percentage of patients with squamous cell lung cancers who experience shrinkage of their tumors following treatment with this regimen. This combination of drugs is not a standard therapy for patients with squamous cell lung cancers. However, each of these drugs, when given alone or with other chemotherapies, is FDA-approved for the treatment of this disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 17, 2015
Enrollment StartAug 1, 2015
Primary CompletionMay 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 10.9 years ago

Interventions

albumin-bound paclitaxeldrug

gemcitabinedrug